vTv Therapeutics to present at May investor conferences on diabetes drug cadisegliatin progress

vTv Therapeutics announced its management will participate in two investor conferences in May to discuss progress on cadisegliatin, a novel oral therapy for type 1 diabetes currently in Phase 3 trials. The company aims to highlight cadisegliatin's potential as a first-in-class adjunctive treatment to insulin, with FDA Breakthrough Therapy designation. Live webcasts of the presentations will be available, providing investors insight into the drug's development and future prospects. This engagement reflects vTv's ongoing efforts to advance treatments for chronic diseases like diabetes.